Seminars in thrombosis and hemostasis最新文献_第2页

Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience. 狼疮抗凝血测试的可变性能:澳大利亚/亚太经验。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-11-15 DOI: 10.1055/s-0043-1776406

Emmanuel J Favaloro, Elysse Dean, Sandya Arunachalam

{"title":"Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience.","authors":"Emmanuel J Favaloro, Elysse Dean, Sandya Arunachalam","doi":"10.1055/s-0043-1776406","DOIUrl":"10.1055/s-0043-1776406","url":null,"abstract":"Lupus anticoagulant (LA) is one of three tests identified as laboratory criteria for definite antiphospholipid syndrome (APS). The other two tests are anticardiolipin antibody (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibody. The presence of LA is assessed using clot-based tests, while the presence of aCL and aβ2GPI is assessed by immunological assays. Since no test can be considered 100% sensitive or specific for LA, current guidelines recommend using two different clot-based assays reflecting different principles, with the dilute Russell viper venom time (dRVVT) and activated partial thromboplastin time (aPTT) recommended. Initially, LA-sensitive reagents are used to screen for LA, and then, in \"screen-positive\" samples, LA-\"insensitive\" reagents are used to confirm LA. Because LA assays are based on clot detection, anything that can interfere with fibrin clot development may affect test results. In particular, in addition to LA, the tests are also sensitive to the presence of a wide range of clinical anticoagulants, reflecting preanalytical issues for testing. We provide updated findings for LA testing in our geographic region, using recent data from the Royal College of Pathologists of Australasia Quality Assurance Programs, an international external quality assessment program with approximately 120 participants. Data show a wide variety of assays in use, especially for aPTT testing, and variable outcomes in reported numerical values with these assays when assessing proficiency samples. dRVVT testing mostly comprised reagents from three main manufacturing suppliers, which also showed differences in numerical values for the same homogeneous tested samples. Nevertheless, despite the use of different test reagents and processes, >98% of participants correctly identified LA-negative samples as LA-negative and LA-positive samples as LA positive. We hope our findings, reflecting on the heterogeneity of test processes and test data, help improve diagnostic testing for LA in the future.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1103-1113"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Internal Quality Control in Hemostasis Assays. 止血试验的内部质量控制。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-09-25 DOI: 10.1055/s-0043-1774381

Christopher Reilly-Stitt, Ian Jennings, Steve Kitchen, Isobel D Walker

{"title":"Internal Quality Control in Hemostasis Assays.","authors":"Christopher Reilly-Stitt, Ian Jennings, Steve Kitchen, Isobel D Walker","doi":"10.1055/s-0043-1774381","DOIUrl":"10.1055/s-0043-1774381","url":null,"abstract":"Internal quality control (IQC) for routine and specialist hemostasis testing represents a mandatory requirement for assays offered by clinical laboratories under International Organization for Standardization, Code of Federal Regulations, and Clinical and Laboratory Standards Institute standards. The underlying principle is that regular IQC audits the analytical performance of automated, semiautomated, and manual methods. This review investigates IQC practices, including benefits, limitations, frequency per time period or batch, sources of material used, primary supplier, third party or in-house, plus troubleshooting when IQC falls outside acceptance criteria. To assess IQC practice, the UK National External Quality Assessment Scheme (NEQAS) Blood Coagulation distributed a questionnaire to 1,200 participants enrolled in our scheme that collected details of the local practices for IQC testing. We received returns from 127 centers that described their local practices for the frequency of IQC, the type of IQC material employed, acceptance criteria for IQC data, and troubleshooting protocols for IQC failures. The data collected as part of an NEQAS BC questionnaire confirmed that all the participants returning answers to the questionnaire meet the standards for regular IQC testing for the hemostasis assays they perform.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1084-1090"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents. 在使用埃米珠单抗或其他新型/新兴止血剂的情况下进行因子检测的策略。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1055/s-0044-1787189

Geoffrey Kershaw

{"title":"Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents.","authors":"Geoffrey Kershaw","doi":"10.1055/s-0044-1787189","DOIUrl":"10.1055/s-0044-1787189","url":null,"abstract":"For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products. The hemostasis laboratory must adapt to the changing landscape by adding new assays or modifying existing assays to ensure accurate results for product measurement. These strategies include switching from a chromogenic assay to a clotting assay, or vice versa, changing an aPTT reagent brand, or introducing product specific calibrators. This article evaluates the effects of some of the newer treatment options on the laboratory testing of factor levels and related assays.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1163-1172"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombophilia Screening: Not So Straightforward. 血栓性疾病筛查：没那么简单

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-05-11 DOI: 10.1055/s-0044-1786807

Gary W Moore

{"title":"Thrombophilia Screening: Not So Straightforward.","authors":"Gary W Moore","doi":"10.1055/s-0044-1786807","DOIUrl":"10.1055/s-0044-1786807","url":null,"abstract":"Although inherited thrombophilias are lifelong risk factors for a first thrombotic episode, progression to thrombosis is multifactorial and not all individuals with inherited thrombophilia develop thrombosis in their lifetimes. Consequently, indiscriminate screening in patients with idiopathic thrombosis is not recommended, since presence of a thrombophilia does not necessarily predict recurrence or influence management, and testing should be selective. It follows that a decision to undertake laboratory detection of thrombophilia should be aligned with a concerted effort to identify any significant abnormalities, because it will inform patient management. Deficiencies of antithrombin and protein C are rare and usually determined using phenotypic assays assessing biological activities, whereas protein S deficiency (also rare) is commonly detected with antigenic assays for the free form of protein S since available activity assays are considered to lack specificity. In each case, no single phenotypic assay is capable of detecting every deficiency, because the various mutations express different molecular characteristics, rendering thrombophilia screening repertoires employing one assay per potential deficiency, of limited effectiveness. Activated protein C resistance (APCR) is more common than discrete deficiencies of antithrombin, protein C, and protein S and also often detected initially with phenotypic assays; however, some centres perform only genetic analysis for factor V Leiden, as this is responsible for most cases of hereditary APCR, accepting that acquired APCR and rare F5 mutations conferring APCR will go undetected if only factor V Leiden is evaluated. All phenotypic assays have interferences and limitations, which must be factored into decisions about if, and when, to test, and be given consideration in the laboratory during assay performance and interpretation. This review looks in detail at performance and limitations of routine phenotypic thrombophilia assays.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1131-1152"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls. 国际血液学标准化委员会凝固试剂、校准器和对照品新批号验证指南。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-11-15 DOI: 10.1055/s-0043-1776405

Robert C Gosselin, Donna Castellone, Akbar Dorgalaleh, Kieron Hickey, Giuseppe Lippi, Karen Moffat, Rebecca O'Toole, Joe Rigano

引用次数: 0

Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice. 肝素的多生物效应及其在临床实践中的监控。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-05-29 DOI: 10.1055/s-0044-1786990

Deepa J Arachchillage, Steve Kitchen

{"title":"Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice.","authors":"Deepa J Arachchillage, Steve Kitchen","doi":"10.1055/s-0044-1786990","DOIUrl":"10.1055/s-0044-1786990","url":null,"abstract":"Unfractionated heparin (UFH) was uncovered in 1916, has been used as an anticoagulant since 1935, and has been listed in the World Health Organization's Model List of Essential Medicines. Despite the availability of many other anticoagulants, the use of heparin (either low molecular weight heparin [LMWH] or UFH) is still substantial. Heparin has pleotropic effects including anticoagulant and several nonanticoagulant properties such as antiproliferative, anti-inflammatory activity, and anticomplement effects. Although UFH has been widely replaced by LMWH, UFH is still the preferred anticoagulant of choice for patients undergoing cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, and patients with high-risk mechanical cardiac valves requiring temporary bridging with a parenteral anticoagulant. UFH is a highly negatively charged molecule and binds many positively charged molecules, hence has unpredictable pharmacokinetics, and variable anticoagulant effect on an individual patient basis. Therefore, anticoagulant effects of UFH may not be proportional to the dose of UFH given to any individual patient. In this review, we discuss the anticoagulant and nonanticoagulant activities of UFH, differences between UFH and LMWH, when to use UFH, different methods of monitoring the anticoagulant effects of UFH (including activated partial thromboplastin time, heparin anti-Xa activity level, and activated clotting time), while discussing pros and cons related to each method and comparison of clinical outcomes in patients treated with UFH monitored with different methods based on available evidence.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1153-1162"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2023 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. 2023 年埃伯哈德-马门奖公告：第二部分 - 青年研究员奖。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-01 DOI: 10.1055/s-0044-1787989

Emmanuel J Favaloro

引用次数: 0

New STH 2023 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics. 新 STH 2023 影响因子、高被引论文及其他期刊指标。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1055/s-0044-1788566

Emmanuel J Favaloro

引用次数: 0

Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden. 活性蛋白C抗性和因子V莱顿的实验室诊断。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-07-10 DOI: 10.1055/s-0043-1770773

Mehran Bahraini, Alieh Fazeli, Akbar Dorgalaleh

引用次数: 0

Laboratory Diagnostics for Thrombosis and Hemostasis Testing-Part III. 血栓与止血检测的实验室诊断--第 3 部分。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1055/s-0044-1788567

Kristi J Smock, Karen A Moffat

引用次数: 0